Nexo Australia has obtained Credit Representative status under the National Consumer Credit Protection Act and will launch its crypto-backed credit lines in Australia starting August 18, 2026. This marks a shift for the operator from a simple trading platform to a regulated credit provider, with all the protections that Australian law imposes on those lending money to consumers. Nexo thus becomes one of the few digital platforms in the country to offer credit backed by digital assets within a fully recognized regulatory framework.
The authorization as a Credit Representative places Nexo Australia under the direct supervision of the National Consumer Credit Protection Act, the law that regulates consumer credit in the country. This is a significant detail: it means that those borrowing liquidity through Nexo have access to the same protections provided for any other regulated loan, not a crypto product outside the scope of oversight.
To strengthen the compliance framework, Nexo Australia is locally incorporated, registered with AUSTRAC as a Virtual Asset Service Provider, and is a member of the Australian Financial Complaints Authority. These three elements combined explain why the company refers to crypto-backed credit in Australia as a "regulated" product and not simply available.
The Credit Lines allow eligible customers to obtain liquidity using their digital assets as collateral, without having to sell them. This enables them to maintain long-term exposure to the market while accessing liquid funds, typically available within 24 hours.
Interest rates vary from 0.9% to 21.9% p.a., based on the customer's loyalty level and the version of the credit line chosen. There are no fixed terms, no origination fees, and repayments are flexible—conditions designed to differentiate from traditional bank loans.
Among the included features stands out the Collateral Exchange, which allows for the exchange between eligible collateral assets without interrupting the active credit line, useful for rebalancing the portfolio when market conditions change. The Nexo Booster is also added, enabling customers to multiply their collateral in digital assets by up to three times, using new positions as additional collateral.
On the practical side, Nexo is among the few digital asset credit providers in Australia to offer payments in both AUD and stablecoins, with a dedicated AUD account number for each local customer --- a choice that reduces delays and errors typical of transfers to crypto platforms.
The company's yield product returns to the local market under the name Nexo Growth, promising up to 10% annual returns on supported assets. Rates vary by asset and duration, and returns are not guaranteed. Customers can choose between Flexible Growth, with daily accumulation and withdrawal on demand, or Fixed-term Growth, which offers a higher rate for a set period.
Around these products revolves the loyalty program Wealth Club, which rewards the use of the platform with better rates on credit lines, cashback, and lifestyle benefits distributed across four levels. The program has been recognized as the best loyalty program for wealth clients in the Digital CX category at The Digital Banker’s Digital CX Awards 2025.
With Credit Lines, Booster, Wealth Club, Exchange, and Growth gathered under a single platform, Nexo aims to cover the entire lifecycle of the crypto customer: buying, growing, borrowing, and managing assets without having to go through separate services.
The launch comes at a time when nearly one in three Australians owns cryptocurrencies, while fixed-term personal credit in the country reached AUD 9.8 billion in the first quarter of 2026, up 14.5% year-on-year. According to Peter Stanhope, General Manager for Australia at Nexo, "the Australian market is ready for a more integrated model" and the products have been built by evaluating each component against the applicable regulatory framework, incorporating regulatory requirements and consumer protections from the outset.
This type of guarantees is not a minor detail. Scamwatch data cited by The Guardian shows that Australians have already lost over AUD 45 million in fraudulent investment schemes in 2026, following AUD 160 million in reported losses in 2025 --- scams often constructed with artificial intelligence on fake crypto trading platforms. In such a climate of distrust, the fact that a crypto-backed credit provider in Australia operates under the National Consumer Credit Protection Act, with AUSTRAC registration and AFCA membership, becomes a concrete competitive argument: for a customer evaluating where to entrust their digital assets, the difference between a regulated platform and an app downloaded from an online ad can be the difference between a loan and a scam.
The launch also fits into Nexo's already established presence in Australia, where the company was the first Official Crypto Partner of the Australian Open. Globally, Nexo Group positions itself as one of the largest crypto lenders, with over $7 billion in assets under management and clients in more than 200 jurisdictions.
Nexo Australia is appointed as a Credit Representative under the National Consumer Credit Protection Act, is registered with AUSTRAC as a Virtual Asset Service Provider, and is a member of AFCA.
Credit Lines allow eligible customers to obtain liquidity using their digital assets as collateral without having to sell them, thus maintaining long-term exposure to the market.
Rates range from 0.9% to 21.9% annually, depending on loyalty level and credit line version. There are no fixed terms, no activation fees, and repayments are flexible.
Features include payments in AUD or stablecoins with a dedicated AUD account number, Collateral Exchange to swap collateral assets without interrupting credit, and Nexo Booster to multiply collateral up to three times.
Content created with the assistance of artificial intelligence and human editorial review.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.














Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.